Loading clinical trials...
Loading clinical trials...
A Randomized Double-Blind, Sponsor-Open, Double-Dummy, Proof of Concept Phase 2 Study to Evaluate the Efficacy and Safety of TAK-951 Versus Ondansetron in the Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Subjects
Conditions
Interventions
TAK-951
Ondansetron
+2 more
Locations
7
United States
Helen Keller Hospital
Sheffield, Alabama, United States
Lotus Clinical Research Inc
Pasadena, California, United States
Phoenix Clinical Research
Tamarac, Florida, United States
Stony Brook Medicine - Hospital
Stony Brook, New York, United States
First Street Hospital - Research
Bellaire, Texas, United States
Legent Orthopedic Hospital
Carrollton, Texas, United States
Start Date
October 20, 2020
Primary Completion Date
March 7, 2022
Completion Date
March 21, 2022
Last Updated
April 21, 2023
NCT06937684
NCT07201883
NCT07421817
NCT07315412
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions